Improved myocardial perfusion in transplanted hearts after apheresis treatment
Claire Braybrook
This article has no abstract so we have provided the first paragraph of the full text.
Cardiac allograft vasculopathy (CAV) is associated with poor outcomes in heart transplant recipients. As elevated levels of blood compounds, including cholesterol, C-reactive protein and fibrinogen, have been linked with increased incidence of CAV, some patients have been treated with statins and heparin-mediated extracorporeal LDL/fibrinogen precipitation (HELP)-apheresis following heart transplantation. Although the efficacy of HELP-apheresis treatment regarding reduction of these blood compounds is well known, its effect on myocardial blood flow and transplant outcome has not been investigated fully.
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.
